Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. Solini A, et al. Diabetes Obes Metab. 2017 Sep;19(9):1289-1294. doi: 10.1111/dom.12970. Epub 2017 May 22. Diabetes Obes Metab. 2017. PMID: 28419670
METHODS: We measured SGLT2 and SGLT1 expression in unaffected renal tissue from 19 people with T2DM and 20 people without diabetes, matched for age and estimated glomerular filtration rate (controls), undergoing unilateral nephrectomy. ...CONCLU …
METHODS: We measured SGLT2 and SGLT1 expression in unaffected renal tissue from 19 people with T2DM and 2 …
Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model.
Shepard BD, Koepsell H, Pluznick JL. Shepard BD, et al. Am J Physiol Renal Physiol. 2019 Feb 1;316(2):F372-F381. doi: 10.1152/ajprenal.00069.2018. Epub 2018 Nov 28. Am J Physiol Renal Physiol. 2019. PMID: 30484350 Free PMC article.
Inhibition of Sglt2 is accepted as a viable therapeutic treatment option for patients with type 2 diabetes and has been shown to delay development of diabetic kidney disease. ...In addition, male and female WT mice developed diabetes-induced hyp …
Inhibition of Sglt2 is accepted as a viable therapeutic treatment option for patients with type 2 diabetes …
Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H, Cleasby ME, Srai SK, Unwin RJ, Debnam ES, Marks J. Chichger H, et al. Exp Physiol. 2016 Jun 1;101(6):731-42. doi: 10.1113/EP085670. Epub 2016 May 10. Exp Physiol. 2016. PMID: 27164183 Free article.
What is the central question of this study? Although SGLT2 inhibitors represent a promising treatment for patients suffering from diabetic nephropathy, the influence of metabolic disruption on the expression and function of glucose transporters is largely unk …
What is the central question of this study? Although SGLT2 inhibitors represent a promising treatment for patients suffering f …